HOWLライブシグナル | Getagraph.comで利益を最大化

買う 114751 min ago

@ $6.85

発行日: 10 2月 2024 @ 00:56

リターン: -1.46%

前回のシグナル: 2月 9 - 01:03

前回のシグナル: 売る

リターン: 3.95 %

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 05:00):

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer...

Stats
本日の出来高	82 000.00
平均出来高	238 830
時価総額	288.48M
EPS	$0 ( 2024-03-28 )
次の収益日	( $-0.350 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-6.43
ATR14	$0.0190 (0.28%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-04	Atkins Michael B.	Buy	35 000	Stock Option (right to buy)
2024-01-04	Atkins Michael B.	Sell	0	Common Stock
2024-01-02	Trost Timothy W.	Buy	150 000	Stock Option (right to buy)
2024-01-02	Lubman Ellen	Buy	131 900	Stock Option (right to buy)
2024-01-02	Isaacs Randi	Buy	200 000	Stock Option (right to buy)

INSIDER POWER
99.27
Last 97 transactions
Buy: 45 258 272 \| Sell: 143 550 934

ボリューム相関

長: 0.24 (neutral)

短: -0.36 (neutral)

Signal:(59.175) Neutral

Werewolf Therapeutics, 相関

10 最も正の相関
RMRM	0.939
APOP	0.918
FEYE	0.897
SVOK	0.88
TLGT	0.879
SVAC	0.874
GAINL	0.874
PAIC	0.861
SYBX	0.854
TDAC	0.851

10 最も負の相関
MMAC	-0.959
AMRB	-0.922
BOCH	-0.893
NETE	-0.888
RGP	-0.851
SBBP	-0.823
SHSP	-0.809

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Werewolf Therapeutics, 相関 - 通貨/商品

0.85
( strong )

0.86
( strong )

0.00
( neutral )

0.88
( strong )

0.23
( neutral )

-0.81
( strong negative )

Werewolf Therapeutics, 財務諸表

Annual	2023
収益:	$19.94M
総利益:	$18.18M (91.15 %)
EPS:	$-1.050

FY	2023
収益:	$19.94M
総利益:	$18.18M (91.15 %)
EPS:	$-1.050

FY	2022
収益:	$16.40M
総利益:	$13.89M (84.70 %)
EPS:	$-1.790

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-5.57

Financial Reports:

No articles found.

Werewolf Therapeutics,

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.